Is it time to stop wringing our hands over one of the most inexpensive cancer screening tools ever dreamt up? An updated meta-analysis pooled all five major randomized PSA-screening trials (n=721,607) with median follow-up stretching 11 to 23 years. Across studies, PSA-based screening reduced prostate cancer-specific mortality by 9%, translating to roughly 10 fewer prostate cancer deaths per 10,000 men screened. As expected, the mortality signal strengthened with longer follow-up. This does nothing but further support our current more-evolved risk-adapted screening pathways incorporating MRI, novel biomarkers, and active surveillance. | Nguyen, Eur Urol 2026
